This is a routine investor conference appearance with no new material information. Monitor for any subsequent 6-K filings that may contain actual clinical or financial updates, but this filing alone does not warrant a trading action.
Price Chart
Executive Summary
Immuron Ltd filed a 6-K announcing that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The attached presentation materials provide an overview of the company's pipeline (Travelan, IMM-529, ProIBS) and platform technology but contain no new financial data, clinical results, or material corporate developments. This is a routine investor relations activity with no actionable trading implications.
Key Facts
- CEO Steven Lydeamore presenting at Emerging Growth Conference on August 19, 2026.
- Presentation covers existing pipeline: Travelan (travelers' diarrhea), IMM-529 (C. diff), and ProIBS (IBS).
- No new financial data, clinical trial results, or material agreements disclosed.
Financial Impact
No financial impact — routine investor presentation with no new material information.
Risk Factors
- No new data or catalysts disclosed; stock may trade on sentiment around the presentation but without fundamental news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088607 |
| Document: ea0301896-6k_immuron.htm | 0001213900-26-088607 |
| Document: 0001213900-26-088607-index-headers.html | 0001213900-26-088607 |
| Document: 0001213900-26-088607-index.html | 0001213900-26-088607 |
| Document: 0001213900-26-088607.txt | 0001213900-26-088607 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers